New Antibiotic Could Provide Single-Dose Option

English: A ruptured MRSA cyst. (Photo credit: Wikipedia)

English: A ruptured MRSA cyst. (Photo credit: Wikipedia)

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers.

Researchers said the advantage of the new drug, oritavancin, is its potential to curtail what has been a key driver of antibiotic resistance: a tendency for patients to stop taking antibiotics once they feel better. In such instances, the surviving bacteria may become impervious to the drugs designed to fight them.

“The prolonged activity is what makes oritavancin distinctive,” said G. Ralph Corey, M.D., lead author of the study published June 5, 2014, in the New England Journal of Medicine (NEJM). “This drug has a long half-life, which allows for a single-dose treatment.”

Read more . . .

 

The Latest on: New Antibiotic

[google_news title=”” keyword=”New Antibiotic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

 

The Latest on: New Antibiotic

via  Bing News

See Also

 

 

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top